Eagle Health Investments LP Has $52.75 Million Stock Position in argenex SE $ARGX

Eagle Health Investments LP decreased its holdings in argenex SE (NASDAQ:ARGX) by 19.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 62,730 shares of the company’s stock after selling 14,700 shares during the quarter. argenex accounts for approximately 11.6% of Eagle Health Investments LP’s holdings, making the stock its largest position. Eagle Health Investments LP’s holdings in argenex were worth $52,753,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of ARGX. M&T Bank Corp grew its stake in shares of argenex by 20,977.7% in the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after purchasing an additional 774,916 shares in the last quarter. Wellington Management Group LLP boosted its stake in argenex by 80.1% during the third quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after buying an additional 324,653 shares in the last quarter. Two Sigma Investments LP boosted its stake in argenex by 570.3% during the third quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock valued at $216,961,000 after buying an additional 250,278 shares in the last quarter. Woodline Partners LP boosted its stake in argenex by 320.8% during the third quarter. Woodline Partners LP now owns 169,476 shares of the company’s stock valued at $124,999,000 after buying an additional 129,205 shares in the last quarter. Finally, Alkeon Capital Management LLC boosted its stake in argenex by 133.3% during the third quarter. Alkeon Capital Management LLC now owns 175,000 shares of the company’s stock valued at $129,073,000 after buying an additional 100,000 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Wells Fargo & Company raised their target price on argenex from $1,247.00 to $1,260.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research note on Monday, April 20th. Robert W. Baird raised their target price on argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. Zacks Research raised argenex from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. Finally, Guggenheim raised their target price on argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $1,017.78.

argenex Stock Up 0.8%

Shares of NASDAQ ARGX opened at $804.25 on Thursday. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The company has a market cap of $49.77 billion, a price-to-earnings ratio of 35.81, a P/E/G ratio of 1.26 and a beta of 0.46. The business has a fifty day simple moving average of $764.13 and a 200-day simple moving average of $815.95.

argenex (NASDAQ:ARGX) last announced its earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%.The business had revenue of $1.31 billion during the quarter. As a group, sell-side analysts expect that argenex SE will post 25.27 EPS for the current fiscal year.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.